ArchiMed announced this week the closing of its $1.1 billion take‑private of Esperion Therapeutics, a biopharmaceutical company focused on bringing cardiometabolic and rare/orphan disease therapies to market. The transaction values Esperion at a premium and gives ArchiMed full control over the company’s pipeline and commercial operations.

The deal follows a series of faster product debuts that have strengthened Esperion’s financial outlook and made the take‑private attractive to investors. In parallel, private equity firms such as KKR, Ares Management, and Tiger Infrastructure Partners are actively scouting opportunities in emergency medical services, driven by a steady rise in ambulance calls nationwide.

These ambulance‑service pursuits reflect a broader trend where PE sponsors are allocating capital to healthcare‑related assets that demonstrate resilient demand and predictable cash flows. ArchiMed’s move underscores confidence in Esperion’s ability to deliver innovative treatments for high‑need patient populations.

Together, the biopharma take‑private and the ambulance‑sector interest illustrate how strategic product launches and sector‑specific opportunities are shaping private equity activity across both therapeutic and services segments of the healthcare industry.